Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04859296

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

Analgesic and Appetite-stimulating Effects of Cannabigerol Administered Alone and in Combination With Delta-9-tetrahydrocannabinol

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
University of California, Los Angeles · Academic / Other
Sex
All
Age
21 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.

Detailed description

The overall aim of this double-blind, placebo-controlled, within-subject study in healthy, occasional cannabis smokers is to ascertain the dose-dependent analgesic and appetite-stimulating effects of ecologically relevant doses of cannabigerol (CBG) alone and in combination with a sub-analgesic / sub-appetite stimulating, minimally psychoactive dose of THC and an analgesic, appetite-stimulating, but intoxicating dose of THC.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboVaporized placebo
DRUGLow CBGVaporized CBG (5 mg)
DRUGHigh CBGVaporized CBG (15 mg)
DRUGLow THCVaporized THC (5 mg)
DRUGHigh THCVaporized THC (15 mg)

Timeline

Start date
2023-02-15
Primary completion
2025-12-04
Completion
2026-12-04
First posted
2021-04-26
Last updated
2026-03-20

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04859296. Inclusion in this directory is not an endorsement.